Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.53 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.51 |
| ▸ | ALB | P02768 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.48 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 2/20 | 0.46 |
| ▸ | CES1 | P23141 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.46 |
| ▸ | TTR | P02766 | 1/20 | 0.46 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30462062 | 1.00 | TSHR (0.63) | TSHRALDH1A1NOTUMKAT6AALB | |
| Hydrochloric Acid SCHEMBL10557491 | 0.98 | TSHR (0.61) | TSHRALDH1A1NOTUMKAT6AALB | |
| SCHEMBL336107 | 0.84 | ALDH1A1 (0.60) | TSHRALDH1A1ALBALOX15CES2 | |
| SCHEMBL25209969 | 0.83 | TSHR (0.46) | TSHRALDH1A1NOTUMKAT6AALB | |
| SCHEMBL29454770 | 0.83 | ALDH1A1 (0.54) | TSHRALDH1A1NOTUMKAT6AALOX15 | |
| SCHEMBL9693738 | 0.83 | KAT6A (0.47) | TSHRALDH1A1NOTUMKAT6AALB | |
| SCHEMBL413285 | 0.83 | ALDH1A1 (0.54) | TSHRALDH1A1NOTUMKAT6AALOX15 | |
| SCHEMBL29975438 | 0.81 | PBRM1 (0.49) | TSHRALDH1A1KAT6APBRM1CES2 | |
| SCHEMBL3612002 | 0.81 | KAT6A (0.46) | TSHRALDH1A1NOTUMKAT6ACES2 | |
| SCHEMBL2175638 | 0.81 | PBRM1 (0.49) | TSHRALDH1A1KAT6APBRM1CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 457 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113943243-B | Preparation and application of fluorine probe for simultaneously identifying and quantifying amino acid | 南开大学 | 2023-08-01 | — | — | CN | claimed |
| CN-113943243-A | Preparation and application of fluorine probe for simultaneously identifying and quantifying amino acid | 南开大学 | 2022-01-18 | — | — | CN | claimed |
| EP-3551633-B1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA AS (DK) | 2021-03-31 | — | — | EP | claimed |
| EP-3551633-A1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | Leo Pharma A/S (DK) | 2019-10-16 | — | — | EP | claimed |
| CN-109293503-A | A kind of preparation method of the fluoro- 3- chlorobenzoic acid of 2,4,5- tri- | 浙江工业大学上虞研究院有限公司 | 2019-02-01 | — | — | CN | claimed |
| WO-2018108230-A1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2018-06-21 | — | — | WO | claimed |
| WO-2018057219-A1 | METHOD OF ALLOCATING INDIVIDUAL OIL OR WATER PRODUCTION CONTRIBUTIONS FROM MULTIPLE COMBINED SOURCES | SPECTRUM TRACER SERVICES, LLC (US) | 2018-03-29 | — | — | WO | claimed |
| US-20180080314-A1 | METHOD OF ALLOCATING INDIVIDUAL OIL OR WATER PRODUCTION CONTRIBUTIONS FROM MULTIPLE COMBINED SOURCES | SPECTRUM TRACER SERVICES, LLC | 2018-03-22 | — | — | US | claimed |
| CN-105503562-A | Bis[5-fluro-2-(4'-methoxybenzoyl)]biphenyl and synthetic method thereof | UNIV NANJING SCIENCE & TECH | 2016-04-20 | — | — | CN | claimed |
| CN-104529729-B | The preparation method of the fluoro-3-chlorobenzaldehyde of a kind of 2- | ZHEJIANG YONGTAI TECHNOLOGY CO., LTD. (CN) | 2016-03-30 | — | — | CN | claimed |
| CN-103524487-B | A kind of preparation method of Sitafloxacin | NANJING YOKO BIO-MEDICAL RESEARCH CO., LTD. (CN) | 2015-12-02 | — | — | CN | claimed |
| CN-103073418-B | The preparation method of the fluoro-3-chloro-benzoic acid of a kind of 2- | NINGBO CHEMGOO PHARMACEUTICAL TECHNOLOGY INNOVATION LIMITED (CN) | 2015-10-21 | — | — | CN | claimed |
| CN-104529729-A | Preparation method for 2-fluoro-3-chlorobenzaldehyde | ZHEJIANG YONGTAI TECHNOLOGY CO LTD | 2015-04-22 | — | — | CN | claimed |
| CN-104529735-A | 1-(5-bromo-4-chloro-2-fluorophenyl)-ethanone synthesis method | SUZHOU SHIYA BIOPHARMACEUTICALS INC | 2015-04-22 | — | — | CN | claimed |
| CN-103896921-A | Compounds and compositions as protein kinase inhibitors | NOVARTIS AG | 2014-07-02 | — | — | CN | claimed |
| CN-102725283-B | Compounds and compositions as protein kinase inhibitors | IRM LLC | 2014-02-26 | — | — | CN | claimed |
| CN-103524487-A | Sitafloxacin preparation method | NANJING YOKO BIO MEDICAL RES CO LTD | 2014-01-22 | — | — | CN | claimed |
| CN-103073418-A | Preparation method of 2-fluoro-3-chlorobenzoic acid | NINGBO CHEMGOO PHARMA TECH CO LTD | 2013-05-01 | — | — | CN | claimed |
| US-20110260051-A1 | METHOD FOR DETECTING TRACER COMPOUNDS FOR HYDROCARBON PRODUCTION | TOTAL S.A. (FR) | 2011-10-27 | — | — | US | claimed |
| WO-2025245087-A1 | HETEROCYCLIC COMPOUNDS AS PARG INHIBITORS | SYNNOVATION THERAPEUTICS, INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| EP-4638438-A1 | ALPHA4 BETA7 INTEGRIN ANTAGONISTS AND USES THEREOF | Xinthera, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-12351582-B2 | Aurora kinase inhibitors and uses thereof | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2025-07-08 | — | — | US | disclosed |
| EP-4001276-B1 | AURORA KINASE INHIBITOR AND USE THEREOF | WIGEN BIOMEDICINE TECH SHANGHAI CO LTD (CN) | 2025-06-25 | — | — | EP | disclosed |
| US-12338230-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-12338241-B2 | Bicyclic sulfones and sulfoxides and methods of use thereof | GENENTECH, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| CN-119977947-A | PRMT5 inhibitor, pharmaceutical composition thereof and application of PRMT5 inhibitor in medicines | 广东东阳光药业股份有限公司 | 2025-05-13 | — | — | CN | disclosed |
| US-12275726-B2 | Aurora kinase inhibitors and use thereof | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2025-04-15 | — | — | US | disclosed |
| US-12275727-B2 | Compound containing structure of a five-membered heteroaromatic ring, pharmaceutical compositions thereof and applications thereof | 280 BIO, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| CN-119350335-B | Material with benzopyridine acridine structure and application thereof | 烟台九目化学股份有限公司 | 2025-04-11 | — | — | CN | disclosed |
| US-12264147-B2 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | Propellon Therapeutics Inc. (CA) | 2025-04-01 | — | — | US | disclosed |
| WO-2025054187-A1 | TGR5 ANTAGONISTS AND METHODS OF USE | Sanford Burnham Prebys Medical Discovery Institute (US) | 2025-03-13 | — | — | WO | disclosed |
| CN-119350335-A | Material with benzopyridine acridine structure and application thereof | 烟台九目化学股份有限公司 | 2025-01-24 | — | — | CN | disclosed |
| EP-4488275-A1 | COMPOUND CONTAINING FIVE-MEMBERED HETEROAROMATIC RING STRUCTURE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai Yingli Pharmaceutical Co., Ltd (CN) | 2025-01-08 | — | — | EP | disclosed |
| WO-2024254990-A1 | COMPOUND HAVING HETEROAROMATIC RING STRUCTURE, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 上海璎黎药业有限公司 | 2024-12-19 | — | — | WO | disclosed |
| CN-119143747-A | Heteroaromatic ring structure compound, pharmaceutical composition and application thereof | 上海璎黎药业有限公司 | 2024-12-17 | — | — | CN | disclosed |
| CN-119118983-A | Xanthone compound and intermediate thereof, preparation method, pharmaceutical composition and application | 上海药坦药物研究开发有限公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-118871430-A | DNA polymerase theta inhibitors and uses thereof | 西藏海思科制药有限公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-113195053-B | Amino acid compounds and methods of use | 普利安特治疗公司 | 2024-08-30 | — | — | CN | disclosed |
| US-20240279214-A1 | ALPHA4 BETA7 INEGRIN ANTAGONISTS AND USES THEREOF | XINTHERA, INC. | 2024-08-22 | — | — | US | disclosed |
| US-20240270742-A1 | SUBSTITUTED AMINO ACIDS AS INTEGRIN INHIBITORS | PLIANT THERAPEUTICS INC (US) | 2024-08-15 | — | — | US | disclosed |
| CN-114222740-B | Aurora kinase inhibitor and use thereof | 微境生物医药科技(上海)有限公司 | 2024-07-23 | — | — | CN | disclosed |
| WO-2024138042-A1 | ALPHA4 BETA7 INTEGRIN ANTAGONISTS AND USES THEREOF | XINTHERA, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024138042-A1 | ALPHA4 BETA7 INTEGRIN ANTAGONISTS AND USES THEREOF | XINTHERA, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| CN-111278809-B | Bicyclic sulfones and sulfoxides, and methods of use thereof | 豪夫迈·罗氏有限公司 | 2024-06-25 | — | — | CN | disclosed |
| WO-2024125629-A1 | UREIC COMPOUND AND PHARMACEUTICAL USE THEREOF AS STING INHIBITOR | 中国药科大学 | 2024-06-20 | — | — | WO | disclosed |
| US-20240199583-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2024-06-20 | — | — | US | disclosed |
| US-12012466-B2 | Peptide macrocycles against Acinetobacter baumannii | HOFFMANN-LA ROCHE INC. (US) | 2024-06-18 | — | — | US | disclosed |
| US-11952376-B2 | Substituted amino acids as integrin inhibitors | PLIANT THERAPEUTICS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| CN-117756698-A | Urea compound and medical application thereof as STING inhibitor | 中国药科大学 | 2024-03-26 | — | — | CN | disclosed |
| US-11926617-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2024-03-12 | — | — | US | disclosed |
| EP-4289839-A1 | NOVEL AURORA KINASE INHIBITOR AND USE THEREOF | Wigen Biomedicine Technology (Shanghai) Co., Ltd. (CN) | 2023-12-13 | — | — | EP | disclosed |
| EP-4289839-A1 | NOVEL AURORA KINASE INHIBITOR AND USE THEREOF | Wigen Biomedicine Technology (Shanghai) Co., Ltd. (CN) | 2023-12-13 | — | — | EP | disclosed |
| US-20230364079-A1 | COMPOUND AS BRAIN-PERMEABLE BTK OR HER2 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | CHENGDU HYPERWAY PHARMACEUTICALS CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-20230357208-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | Epizyme, Inc. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230357208-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | Epizyme, Inc. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230357208-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | Epizyme, Inc. (US) | 2023-11-09 | — | — | US | disclosed |
| EP-3704097-B1 | BICYCLIC SULFONES AND SULFOXIDES AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2023-10-25 | — | — | EP | disclosed |
| EP-3340983-B1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2023-10-04 | — | — | EP | disclosed |
| WO-2023169547-A1 | DNA POLYMERASE θ INHIBITOR AND USE THEREOF | 四川海思科制药有限公司 | 2023-09-14 | — | — | WO | disclosed |
| EP-3728267-B1 | TRICYCLIC INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RES OICR (CA) | 2023-09-13 | — | — | EP | disclosed |
| EP-3728267-B1 | TRICYCLIC INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RES OICR (CA) | 2023-09-13 | — | — | EP | disclosed |
| US-20230278998-A1 | Compound containing structure of a five-membered heteroaromatic ring, pharmaceutical compositions thereof and applications thereof | 280 BIO, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230278998-A1 | Compound containing structure of a five-membered heteroaromatic ring, pharmaceutical compositions thereof and applications thereof | 280 BIO, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| WO-2023165571-A1 | COMPOUND CONTAINING FIVE-MEMBERED HETEROAROMATIC RING STRUCTURE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 上海璎黎药业有限公司 | 2023-09-07 | — | — | WO | disclosed |
| US-20230278998-A1 | Compound containing structure of a five-membered heteroaromatic ring, pharmaceutical compositions thereof and applications thereof | 280 BIO, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| CN-116693519-A | Compound containing five-membered heteroaromatic ring structure, pharmaceutical composition and application thereof | 上海璎黎药业有限公司 | 2023-09-05 | — | — | CN | disclosed |
| US-20230257383-A1 | COMPOUND SERVING AS BTK INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | CHENGDU HYPERWAY PHARMACEUTICALS CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| CN-116568683-A | Dibenzofive-membered ring compound and organic electroluminescent device comprising same | 株式会社乐普拓 | 2023-08-08 | — | — | CN | disclosed |
| CN-113943243-B | Preparation and application of fluorine probe for simultaneously identifying and quantifying amino acid | 南开大学 | 2023-08-01 | — | — | CN | disclosed |
| US-20230219926-A1 | SUBSTITUTED CARBOXAMIDES AS INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING | FACIT INC. (CA) | 2023-07-13 | — | — | US | disclosed |
| CN-111434671-B | Liver-specific AMPK agonist and preparation method and application thereof | 凯思凯迪（上海）医药科技有限公司 | 2023-07-11 | — | — | CN | disclosed |
| CN-116348116-A | Pyrimidine compound and medical use thereof | 台湾卫生研究院 | 2023-06-27 | — | — | CN | disclosed |
| US-11685732-B2 | MYST family histone acetyltransferase inhibitors | Epizyme, Inc. (US) | 2023-06-27 | — | — | US | disclosed |
| US-11685732-B2 | MYST family histone acetyltransferase inhibitors | Epizyme, Inc. (US) | 2023-06-27 | — | — | US | disclosed |
| US-11685732-B2 | MYST family histone acetyltransferase inhibitors | Epizyme, Inc. (US) | 2023-06-27 | — | — | US | disclosed |
| WO-2023097386-A1 | SELECTIVE HDAC6-INHIBITING N-ACYLHYDRAZONE COMPOUNDS, METHODS FOR PRODUCING SAME, COMPOSITIONS, USES, TREATMENT METHODS AND KITS | EUROFARMA LABORATÓRIOS S.A (BR) | 2023-06-08 | — | — | WO | disclosed |
| EP-4186905-A1 | COMPOUND SERVING AS BTK INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | Chengdu Hyperway Pharmaceuticals Co., Ltd. (CN) | 2023-05-31 | — | — | EP | disclosed |
| EP-4186906-A1 | COMPOUND AS BRAIN-PERMEABLE BTK OR HER2 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | Chengdu Hyperway Pharmaceuticals Co., Ltd. (CN) | 2023-05-31 | — | — | EP | disclosed |
| CN-116143738-A | Anthracene asymmetric dibenzoheterocyclic compound and application thereof | 烟台显华科技集团股份有限公司 | 2023-05-23 | — | — | CN | disclosed |
| US-20230131830-A1 | PYRIMIDINE COMPOUNDS AND THEIR PHARMACEUTICAL USES | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2023-04-27 | — | — | US | disclosed |
| US-20230131830-A1 | PYRIMIDINE COMPOUNDS AND THEIR PHARMACEUTICAL USES | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2023-04-27 | — | — | US | disclosed |
| US-20230131830-A1 | PYRIMIDINE COMPOUNDS AND THEIR PHARMACEUTICAL USES | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2023-04-27 | — | — | US | disclosed |
| CN-114072400-B | Aurora kinase inhibitor and use thereof | 微境生物医药科技(上海)有限公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-115916759-A | Substituted quinazoline compound, preparation method, pharmaceutical composition and application thereof | 南京红云生物科技有限公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-111138366-B | Pyrazole carbamoyl derivatives, preparation method and application thereof | 天津药物研究院有限公司 | 2023-03-28 | — | — | CN | disclosed |
| CN-114644635-B | Triazole tricyclic derivative and preparation method and application thereof | 上海济煜医药科技有限公司 | 2023-02-03 | — | — | CN | disclosed |
| US-20230002391-A1 | BICYCLIC SULFONES AND SULFOXIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2023-01-05 | — | — | US | disclosed |
| US-20220411468-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | HOFFMANN-LA ROCHE INC. (US) | 2022-12-29 | — | — | US | disclosed |
| US-11518764-B2 | Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interaction | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-12-06 | — | — | US | disclosed |
| US-11518764-B2 | Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interaction | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-12-06 | — | — | US | disclosed |
| EP-4087574-A1 | PYRIMIDINE COMPOUNDS AND THEIR PHARMACEUTICAL USES | National Health Research Institutes (TW) | 2022-11-16 | — | — | EP | disclosed |
| US-20220324857-A1 | NOVEL AURORA KINASE INHIBITORS AND USE THEREOF | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2022-10-13 | — | — | US | disclosed |
| US-20220315562-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2022-10-06 | — | — | US | disclosed |
| US-20220289685-A1 | ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES | UCB BIOPHARMA SRL (SOCIETE A RESPONSABILITE LIMITEE) (BE) | 2022-09-15 | — | — | US | disclosed |
| US-20220289720-A1 | ARYL SULFONAMIDES AS SMALL MOLECULE STAT3 INHIBITORS | UNIVERSITY OF HAWAII | 2022-09-15 | — | — | US | disclosed |
| EP-3423451-B1 | INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING | PROPELLON THERAPEUTICS INC (CA) | 2022-08-17 | — | — | EP | disclosed |
| US-11407738-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2022-08-09 | — | — | US | disclosed |
| WO-2022156788-A1 | BENZIMIDAZOLE COMPOUND AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2022-07-28 | — | — | WO | disclosed |
| EP-3749672-B1 | INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RES OICR (CA) | 2022-07-27 | — | — | EP | disclosed |
| CN-109195965-B | Inhibitors of WDR5 protein-protein binding | 普罗佩纶治疗公司 | 2022-07-26 | — | — | CN | disclosed |
| CN-114773331-A | Benzimidazole compounds and uses thereof | 武汉人福创新药物研发中心有限公司 | 2022-07-22 | — | — | CN | disclosed |
| WO-2022135335-A1 | TRIAZOLE TRICYCLIC DERIVATIVE AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海济煜医药科技有限公司 | 2022-06-30 | — | — | WO | disclosed |
| EP-4017591-A1 | ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES | UCB Biopharma SRL (BE) | 2022-06-29 | — | — | EP | disclosed |
| CN-114644635-A | Triazole tricyclic derivative and preparation method and application thereof | 上海济煜医药科技有限公司 | 2022-06-21 | — | — | CN | disclosed |
| US-20220162197-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | Epizyme, Inc. | 2022-05-26 | — | — | US | disclosed |
| US-20220162197-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | Epizyme, Inc. | 2022-05-26 | — | — | US | disclosed |
| EP-4001276-A1 | AURORA KINASE INHIBITOR AND USE THEREOF | Wigen Biomedicine Technology (Shanghai) Co., Ltd. (CN) | 2022-05-25 | — | — | EP | disclosed |
| EP-4001276-A1 | AURORA KINASE INHIBITOR AND USE THEREOF | Wigen Biomedicine Technology (Shanghai) Co., Ltd. (CN) | 2022-05-25 | — | — | EP | disclosed |
| US-20220144829-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2022-05-12 | — | — | US | disclosed |
| US-11319299-B2 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | Propellon Therapeutics Inc. (CA) | 2022-05-03 | — | — | US | disclosed |
| CN-109311860-B | Xanthone derivatives for the treatment or prevention of hepatitis B virus diseases | 豪夫迈·罗氏有限公司 | 2022-04-08 | — | — | CN | disclosed |
| CN-114222740-A | Novel aurora kinase inhibitor and use thereof | 微境生物医药科技(上海)有限公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-114206856-A | Anti-malarial hexahydropyrimidine analogues | UCB生物制药有限责任公司 | 2022-03-18 | — | — | CN | disclosed |
| CN-114072400-A | Aurora kinase inhibitor and use thereof | 微境生物医药科技(上海)有限公司 | 2022-02-18 | — | — | CN | disclosed |
| US-11242351-B2 | Tricyclic inhibitors of the BCL6 BTB domain protein-protein interaction and uses thereof | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-02-08 | — | — | US | disclosed |
| US-11242351-B2 | Tricyclic inhibitors of the BCL6 BTB domain protein-protein interaction and uses thereof | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-02-08 | — | — | US | disclosed |
| US-11229638-B2 | Therapeutic heterocyclic compounds | GILEAD SCIENCES, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| CN-113943243-A | Preparation and application of fluorine probe for simultaneously identifying and quantifying amino acid | 南开大学 | 2022-01-18 | — | — | CN | disclosed |
| WO-2021254464-A1 | SUBSTITUTED QUINAZOLINE COMPOUND, AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 南京红云生物科技有限公司 | 2021-12-23 | — | — | WO | disclosed |
| CN-108350028-B | Peptide macrocycles against Acinetobacter baumannii | 豪夫迈·罗氏有限公司 | 2021-12-07 | — | — | CN | disclosed |
| US-11180494-B2 | Substituted amino acids as integrin inhibitors | PLIANT THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20210289794-A1 | COMPOSITIONS AND RELATED METHODS FOR AGRICULTURE | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-09-23 | — | — | US | disclosed |
| WO-2021178485-A1 | PYRIMIDINE COMPOUNDS AND THEIR PHARMACEUTICAL USES | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2021-09-10 | — | — | WO | disclosed |
| WO-2021178485-A1 | PYRIMIDINE COMPOUNDS AND THEIR PHARMACEUTICAL USES | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2021-09-10 | — | — | WO | disclosed |
| EP-3863711-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | Pliant Therapeutics, Inc. (US) | 2021-08-18 | — | — | EP | disclosed |
| CN-113195053-A | Amino acid compounds and methods of use | 普利安特治疗公司 | 2021-07-30 | — | — | CN | disclosed |
| US-11072617-B2 | Bicyclic sulfones and sulfoxides and methods of use thereof | GENENTECH, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| US-20210198261-A1 | AURORA KINASE INHIBITORS AND USES THEREOF | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2021-07-01 | — | — | US | disclosed |
| US-20210198261-A1 | AURORA KINASE INHIBITORS AND USES THEREOF | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2021-07-01 | — | — | US | disclosed |
| US-11040033-B2 | Therapeutic heterocyclic compounds | GILEAD SCIENCES, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| EP-3464278-B1 | XANTHONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | HOFFMANN LA ROCHE (CH) | 2021-06-16 | — | — | EP | disclosed |
| WO-2021110009-A1 | NOVEL AURORA KINASE INHIBITOR AND USE THEREOF | 微境生物医药科技(上海)有限公司 | 2021-06-10 | — | — | WO | disclosed |
| CN-112898292-A | Novel aurora kinase inhibitor and use thereof | 微境生物医药科技(上海)有限公司 | 2021-06-04 | — | — | CN | disclosed |
| WO-2021032687-A1 | ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES | UCB Biopharma SRL (BE) | 2021-02-25 | — | — | WO | disclosed |
| US-20210053978-A1 | TRICYCLIC INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2021-02-25 | — | — | US | disclosed |
| US-20210053978-A1 | TRICYCLIC INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2021-02-25 | — | — | US | disclosed |
| WO-2021016333-A1 | ARYL SULFONAMIDES AS SMALL MOLECULE STAT3 INHIBITORS | UNIVERSITY OF HAWAII (US) | 2021-01-28 | — | — | WO | disclosed |
| WO-2021008338-A1 | AURORA KINASE INHIBITOR AND USE THEREOF | 微境生物医药科技(上海)有限公司 | 2021-01-21 | — | — | WO | disclosed |
| CN-112239465-A | Aurora kinase inhibitor and use thereof | 微境生物医药科技(上海)有限公司 | 2021-01-19 | — | — | CN | disclosed |
| EP-3749672-A1 | INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | Ontario Institute for Cancer Research (OICR) (CA) | 2020-12-16 | — | — | EP | disclosed |
| EP-3728267-A1 | TRICYCLIC INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | Ontario Institute for Cancer Research (OICR) (CA) | 2020-10-28 | — | — | EP | disclosed |
| US-20200331921-A1 | INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2020-10-22 | — | — | US | disclosed |
| US-20200331921-A1 | INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2020-10-22 | — | — | US | disclosed |
| US-20200316035-A1 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | GILEAD SCIENCES, INC. | 2020-10-08 | — | — | US | disclosed |
| EP-3716964-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | Epizyme, Inc. (US) | 2020-10-07 | — | — | EP | disclosed |
| EP-3704097-A1 | BICYCLIC SULFONES AND SULFOXIDES AND METHODS OF USE THEREOF | F. Hoffmann-La Roche AG (CH) | 2020-09-09 | — | — | EP | disclosed |
| CN-111565717-A | Inhibitors of MYST family histone acetyltransferases | EPIZYME股份有限公司 | 2020-08-21 | — | — | CN | disclosed |
| US-20200262818-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-08-20 | — | — | US | disclosed |
| US-20200262818-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-08-20 | — | — | US | disclosed |
| CN-111434671-A | Liver specificity AMPK agonist and preparation method and application thereof | 凯思凯迪（上海）医药科技有限公司 | 2020-07-21 | — | — | CN | disclosed |
| WO-2020143800-A1 | LIVER-SPECIFIC AMPK AGONIST, PREPARATION METHOD THEREFOR AND USES THEREOF | 凯思凯迪（上海）医药科技有限公司 | 2020-07-16 | — | — | WO | disclosed |
| EP-3672970-A1 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | Gilead Sciences, Inc. (US) | 2020-07-01 | — | — | EP | disclosed |
| EP-3368544-B1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | HOFFMANN LA ROCHE (CH) | 2020-06-17 | — | — | EP | disclosed |
| CN-111278809-A | Bicyclic sulfones and sulfoxides, and methods of use thereof | 豪夫迈·罗氏有限公司 | 2020-06-12 | — | — | CN | disclosed |
| US-10662175-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-10662175-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| CN-111138366-A | Pyrazole carbamoyl derivatives, preparation method and application thereof | 天津药物研究院有限公司 | 2020-05-12 | — | — | CN | disclosed |
| CN-111051305-A | Therapeutic heterocyclic compounds | 吉利德科学公司 | 2020-04-21 | — | — | CN | disclosed |
| US-20200109141-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2020-04-09 | — | — | US | disclosed |
| US-10611748-B2 | Xanthone derivatives for the treatment of hepatitis B virus disease | HOFFMANN-LA ROCHE INC. (US) | 2020-04-07 | — | — | US | disclosed |
| US-20200054630-A1 | BENZAMIDES-CONTAINING COMPOUNDS AND THEIR USE IN THE TREATMENT OF DEPRESSION | MINDIMMUNE THERAPEUTICS, INC. | 2020-02-20 | — | — | US | disclosed |
| EP-3551634-A1 | SUBSTITUTED PYRAZOLOAZEPIN-8-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | Leo Pharma A/S (DK) | 2019-10-16 | — | — | EP | disclosed |
| CN-110317150-A | A method of preparing 3,4- dichlorobenzonitrile | 江苏超跃化学有限公司 | 2019-10-11 | — | — | CN | disclosed |
| WO-2019153080-A1 | INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2019-08-15 | — | — | WO | disclosed |
| WO-2019153080-A1 | INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2019-08-15 | — | — | WO | disclosed |
| EP-3215505-B1 | PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE | Bayer Pharma AG (DE) | 2019-07-24 | — | — | EP | disclosed |
| US-20190192504-A1 | Therapeutic heterocyclic compounds | GILEAD SCIENCES, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20190185444-A1 | XANTHONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2019-06-20 | — | — | US | disclosed |
| US-20190127382-A1 | BICYCLIC SULFONES AND SULFOXIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-05-02 | — | — | US | disclosed |
| US-20190112290-A1 | INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING | Propellon Therapeutics Inc. (CA) | 2019-04-18 | — | — | US | disclosed |
| EP-3464278-A1 | XANTHONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | H. Hoffnabb-La Roche Ag (CH) | 2019-04-10 | — | — | EP | disclosed |
| US-10238654-B2 | Benzamides-containing compounds and their use in the treatment of epilepsy | MINDIMMUNE THERAPEUTICS, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| EP-3191112-B1 | DIPEPTIDYL KETOAMIDE COMPOUNDS AND THEIR USE FOR THE TREATMENT AND/OR PREVENTION OF FAT ACCUMULATION | LANDSTEINER GENMED S L (ES) | 2019-03-20 | — | — | EP | disclosed |
| WO-2019040102-A1 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2019-02-28 | — | — | WO | disclosed |
| CN-109293503-A | A kind of preparation method of the fluoro- 3- chlorobenzoic acid of 2,4,5- tri- | 浙江工业大学上虞研究院有限公司 | 2019-02-01 | — | — | CN | disclosed |
| CN-109293503-A | A kind of preparation method of the fluoro- 3- chlorobenzoic acid of 2,4,5- tri- | 浙江工业大学上虞研究院有限公司 | 2019-02-01 | — | — | CN | disclosed |
| CN-109293503-A | A kind of preparation method of the fluoro- 3- chlorobenzoic acid of 2,4,5- tri- | 浙江工业大学上虞研究院有限公司 | 2019-02-01 | — | — | CN | disclosed |
| EP-3423451-A1 | INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING | Propellon Therapeutics Inc. (CA) | 2019-01-09 | — | — | EP | disclosed |
| US-20180369224-A1 | NOVEL PIPERIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-12-27 | — | — | US | disclosed |
| US-20180362578-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | HOFFMANN-LA ROCHE INC. (US) | 2018-12-20 | — | — | US | disclosed |
| US-10118930-B2 | Piperidinylpyrazolopyrimidinones and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-11-06 | — | — | US | disclosed |
| US-10092556-B2 | Piperidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-10-09 | — | — | US | disclosed |
| EP-3055314-B1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-09-12 | — | — | EP | disclosed |
| EP-3368544-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | H. Hoffnabb-La Roche Ag (CH) | 2018-09-05 | — | — | EP | disclosed |
| US-10030047-B2 | Peptide macrocycles against acinetobacter baumannii | HOFFMANN-LA ROCHE INC. (US) | 2018-07-24 | — | — | US | disclosed |
| EP-3340983-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2018-07-04 | — | — | EP | disclosed |
| US-20180179186-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-06-28 | — | — | US | disclosed |
| US-20180179186-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-06-28 | — | — | US | disclosed |
| WO-2018108231-A1 | SUBSTITUTED PYRAZOLOAZEPIN-8-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2018-06-21 | — | — | WO | disclosed |
| US-9946847-B2 | Libraries of compounds having desired properties and methods for making and using them | BIOBLOCKS INC. (US) | 2018-04-17 | — | — | US | disclosed |
| WO-2018057219-A1 | METHOD OF ALLOCATING INDIVIDUAL OIL OR WATER PRODUCTION CONTRIBUTIONS FROM MULTIPLE COMBINED SOURCES | SPECTRUM TRACER SERVICES, LLC (US) | 2018-03-29 | — | — | WO | disclosed |
| US-20180080314-A1 | METHOD OF ALLOCATING INDIVIDUAL OIL OR WATER PRODUCTION CONTRIBUTIONS FROM MULTIPLE COMBINED SOURCES | SPECTRUM TRACER SERVICES, LLC | 2018-03-22 | — | — | US | disclosed |
| EP-2906546-B1 | BENZAMIDES | H LUNDBECK AS (DK) | 2018-01-10 | — | — | EP | disclosed |
| WO-2017202798-A1 | XANTHONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2017-11-30 | — | — | WO | disclosed |
| US-20170334917-A1 | PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-11-23 | — | — | US | disclosed |
| EP-3215505-A1 | PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE | Bayer Pharma Aktiengesellschaft (DE) | 2017-09-13 | — | — | EP | disclosed |
| US-20170233437-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | HOFFMANN-LA ROCHE INC. (US) | 2017-08-17 | — | — | US | disclosed |
| US-20170202836-A1 | Benzamides-Containing Compounds and Their Use in the Treatment of Epilepsy | H. LUNDBECK A/S (DK) | 2017-07-20 | — | — | US | disclosed |
| US-20170136007-A1 | NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | THE FEINSTEIN INST MEDICAL RES (US) | 2017-05-18 | — | — | US | disclosed |
| US-9649308-B2 | Benzamide-containing compounds and their use in the treatment of pain | H. LUNDBECK A/S (DK) | 2017-05-16 | — | — | US | disclosed |
| WO-2017072062-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | F. HOFFMANN-LA ROCHE AG (CH) | 2017-05-04 | — | — | WO | disclosed |
| WO-2017035409-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | WO | disclosed |
| EP-2880017-B1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | GILEAD SCIENCES INC (US) | 2016-10-05 | — | — | EP | disclosed |
| EP-2880017-B1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | GILEAD SCIENCES INC (US) | 2016-10-05 | — | — | EP | disclosed |
| US-9458181-B2 | Cathepsin cysteine protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9428522-B2 | Piperazines, pharmaceutical compositions and methods of use thereof | THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH (US) | 2016-08-30 | — | — | US | disclosed |
| EP-3055314-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-08-17 | — | — | EP | disclosed |
| US-20160228427-A1 | NOVEL PIPERIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
| US-20160228427-A1 | NOVEL PIPERIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
| US-20160228427-A1 | NOVEL PIPERIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
| EP-2821406-B1 | NOVEL PIPERIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2016-06-01 | — | — | EP | disclosed |
| EP-2821406-B1 | NOVEL PIPERIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2016-06-01 | — | — | EP | disclosed |
| US-9346787-B2 | Piperidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2016-05-24 | — | — | US | disclosed |
| US-9346787-B2 | Piperidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2016-05-24 | — | — | US | disclosed |
| US-9346787-B2 | Piperidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2016-05-24 | — | — | US | disclosed |
| WO-2016071216-A1 | PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-05-12 | — | — | WO | disclosed |
| CN-104159893-B | Piperidine compound or salt thereof | TAIHO PHARMACEUTICAL CO.,LTD. (JP) | 2016-05-11 | — | — | CN | disclosed |
| CN-105503562-A | Bis[5-fluro-2-(4'-methoxybenzoyl)]biphenyl and synthetic method thereof | UNIV NANJING SCIENCE & TECH | 2016-04-20 | — | — | CN | disclosed |
| CN-104529729-B | The preparation method of the fluoro-3-chlorobenzaldehyde of a kind of 2- | ZHEJIANG YONGTAI TECHNOLOGY CO., LTD. (CN) | 2016-03-30 | — | — | CN | disclosed |
| CN-101848899-B | As the N-benzyl of LXR conditioning agent, N '-aryl carbonyl bridged piperazine derivatives | MERCK SHARP & DOHME B.V. (NL) | 2016-03-02 | — | — | CN | disclosed |
| CN-103797010-B | As the azetidinyl phenyl of JAK inhibitor, pyridyl or pyrazinyl carboxamides derivatives | INCYTE HOLDINGS CORP. (US) | 2016-02-24 | — | — | CN | disclosed |
| CN-103896921-B | As compound and the composition of kinases inhibitor | IRM LLC (BM) | 2016-02-24 | — | — | CN | disclosed |
| CN-105209464-A | P2x7 modulators | JANSSEN PHARMACEUTICA NV | 2015-12-30 | — | — | CN | disclosed |
| CN-103524487-B | A kind of preparation method of Sitafloxacin | NANJING YOKO BIO-MEDICAL RESEARCH CO., LTD. (CN) | 2015-12-02 | — | — | CN | disclosed |
| CN-103524487-B | A kind of preparation method of Sitafloxacin | NANJING YOKO BIO-MEDICAL RESEARCH CO., LTD. (CN) | 2015-12-02 | — | — | CN | disclosed |
| CN-105073714-A | Peri-carbinols | ALDEXA THERAPEUTICS INC | 2015-11-18 | — | — | CN | disclosed |
| CN-103073418-B | The preparation method of the fluoro-3-chloro-benzoic acid of a kind of 2- | NINGBO CHEMGOO PHARMACEUTICAL TECHNOLOGY INNOVATION LIMITED (CN) | 2015-10-21 | — | — | CN | disclosed |
| CN-103073418-B | The preparation method of the fluoro-3-chloro-benzoic acid of a kind of 2- | NINGBO CHEMGOO PHARMACEUTICAL TECHNOLOGY INNOVATION LIMITED (CN) | 2015-10-21 | — | — | CN | disclosed |
| CN-103073418-B | The preparation method of the fluoro-3-chloro-benzoic acid of a kind of 2- | NINGBO CHEMGOO PHARMACEUTICAL TECHNOLOGY INNOVATION LIMITED (CN) | 2015-10-21 | — | — | CN | disclosed |
| US-20150283134-A1 | Benzamides | MINDIMMUNE THERAPEUTICS, INC. | 2015-10-08 | — | — | US | disclosed |
| US-20150269356-A1 | LIBRARIES OF COMPOUNDS HAVING DESIRED PROPERTIES AND METHODS FOR MAKING AND USING THEM | BIOBLOCKS INC (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150269356-A1 | LIBRARIES OF COMPOUNDS HAVING DESIRED PROPERTIES AND METHODS FOR MAKING AND USING THEM | BIOBLOCKS INC (US) | 2015-09-24 | — | — | US | disclosed |
| CN-104884445-A | Benzamides | LUNDBECK & CO AS H | 2015-09-02 | — | — | CN | disclosed |
| EP-2906546-A1 | BENZAMIDES | H. Lundbeck A/S (DK) | 2015-08-19 | — | — | EP | disclosed |
| US-9102591-B2 | Benzamides | H. LUNDBECK A/S (DK) | 2015-08-11 | — | — | US | disclosed |
| CN-103664927-B | N-[5-(1,2,4-triazole-1-yl)thiazole-2-yl]aryl amide, preparation method, and applications thereof | UNIV HUNAN | 2015-06-24 | — | — | CN | disclosed |
| CN-104718188-A | N-substituted benzamides and their use in the treatment of pain | GENENTECH INC | 2015-06-17 | — | — | CN | disclosed |
| EP-2880017-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | Gilead Sciences, Inc. (US) | 2015-06-10 | — | — | EP | disclosed |
| CN-104529729-A | Preparation method for 2-fluoro-3-chlorobenzaldehyde | ZHEJIANG YONGTAI TECHNOLOGY CO LTD | 2015-04-22 | — | — | CN | disclosed |
| CN-104529735-A | 1-(5-bromo-4-chloro-2-fluorophenyl)-ethanone synthesis method | SUZHOU SHIYA BIOPHARMACEUTICALS INC | 2015-04-22 | — | — | CN | disclosed |
| US-9012475-B2 | Method for enhancing anti-tumor effect of a microtubule-targeting drug, and a method for treatment of tumor | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2015-04-21 | — | — | US | disclosed |
| US-9012475-B2 | Method for enhancing anti-tumor effect of a microtubule-targeting drug, and a method for treatment of tumor | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2015-04-21 | — | — | US | disclosed |
| US-9012475-B2 | Method for enhancing anti-tumor effect of a microtubule-targeting drug, and a method for treatment of tumor | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2015-04-21 | — | — | US | disclosed |
| WO-2015054089-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-04-16 | — | — | WO | disclosed |
| US-20150099719-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK SHARP & DOHME LLC | 2015-04-09 | — | — | US | disclosed |
| EP-2855428-A1 | N-SUBSTITUTED BENZAMIDES AND THEIR USE IN THE TREATMENT OF PAIN | Genentech, Inc. (US) | 2015-04-08 | — | — | EP | disclosed |
| CN-104487433-A | Triazolone compounds as mpges-1 inhibitors | GLENMARK PHARMACEUTICALS SA | 2015-04-01 | — | — | CN | disclosed |
| US-20150065479-A1 | METHOD FOR ENHANCING ANTI-TUMOR EFFECT OF A MICROTUBULE-TARGETING DRUG, AND A METHOD FOR TREATMENT OF TUMOR | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2015-03-05 | — | — | US | disclosed |
| US-20150065479-A1 | METHOD FOR ENHANCING ANTI-TUMOR EFFECT OF A MICROTUBULE-TARGETING DRUG, AND A METHOD FOR TREATMENT OF TUMOR | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2015-03-05 | — | — | US | disclosed |
| US-20150065479-A1 | METHOD FOR ENHANCING ANTI-TUMOR EFFECT OF A MICROTUBULE-TARGETING DRUG, AND A METHOD FOR TREATMENT OF TUMOR | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2015-03-05 | — | — | US | disclosed |
| US-20150045342-A1 | NOVEL PIPERIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2015-02-12 | — | — | US | disclosed |
| US-20150045342-A1 | NOVEL PIPERIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2015-02-12 | — | — | US | disclosed |
| US-20150045342-A1 | NOVEL PIPERIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2015-02-12 | — | — | US | disclosed |
| EP-2821406-A1 | NOVEL PIPERIDINE COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2015-01-07 | — | — | EP | disclosed |
| EP-2821406-A1 | NOVEL PIPERIDINE COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2015-01-07 | — | — | EP | disclosed |
| EP-2254888-B1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | MSD KK (JP) | 2014-12-24 | — | — | EP | disclosed |
| WO-2014184235-A1 | BENZAMIDE TRPA1 ANTAGONISTS | Acturum Life Science AB (SE) | 2014-11-20 | — | — | WO | disclosed |
| US-20140343059-A1 | NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH | 2014-11-20 | — | — | US | disclosed |
| CN-104159893-A | Novel piperidine compound or salt thereof | TAIHO PHARMACEUTICAL CO LTD | 2014-11-19 | — | — | CN | disclosed |
| CN-104144922-A | As EP2Novel 2H-indazoles as receptor antagonists | BAYER IP GMBH | 2014-11-12 | — | — | CN | disclosed |
| US-8877931-B2 | Process and intermediates for preparing integrase inhibitors | GILEAD SCIENCES, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-8877931-B2 | Process and intermediates for preparing integrase inhibitors | GILEAD SCIENCES, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-8877931-B2 | Process and intermediates for preparing integrase inhibitors | GILEAD SCIENCES, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| CN-102482221-B | bicyclic and tricyclic compounds as KATII inhibitors | PFIZER INC. (US) | 2014-10-22 | — | — | CN | disclosed |
| US-8853619-B2 | Method for detecting tracer compounds for hydrocarbon production | TOTAL S.A. (FR) | 2014-10-07 | — | — | US | disclosed |
| US-8853619-B2 | Method for detecting tracer compounds for hydrocarbon production | TOTAL S.A. (FR) | 2014-10-07 | — | — | US | disclosed |
| US-8853619-B2 | Method for detecting tracer compounds for hydrocarbon production | TOTAL S.A. (FR) | 2014-10-07 | — | — | US | disclosed |
| US-8822472-B2 | Piperazines, pharmaceutical compositions and methods of use thereof | CORNERSTONE THERAPEUTICS, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| CN-103987698-A | 2-Phenylaminopyrimidine derivatives as kinase LRRK2 modulators for the treatment of Parkinson's disease | HOFFMANN LA ROCHE | 2014-08-13 | — | — | CN | disclosed |
| CN-103974954-A | Kinase modulating compounds, compositions containing them and uses thereof | CENTAURUS BIOPHARMA CO LTD | 2014-08-06 | — | — | CN | disclosed |
| EP-2044038-B1 | NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | CORNERSTONE THERAPEUTICS INC (US) | 2014-07-02 | — | — | EP | disclosed |
| CN-103896921-A | Compounds and compositions as protein kinase inhibitors | NOVARTIS AG | 2014-07-02 | — | — | CN | disclosed |
| CN-103797010-A | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors | INCYTE CORP | 2014-05-14 | — | — | CN | disclosed |
| US-20140107340-A1 | Benzamides | H. LUNDBECK A/S (DK) | 2014-04-17 | — | — | US | disclosed |
| WO-2014057078-A1 | BENZAMIDES | H. LUNDBECK A/S (DK) | 2014-04-17 | — | — | WO | disclosed |
| WO-2014047463-A2 | LIBRARIES OF COMPOUNDS HAVING DESIRED PROPERTIES AND METHODS FOR MAKING AND USING THEM | BIOBLOCKS, INC. (US) | 2014-03-27 | — | — | WO | disclosed |
| CN-103664927-A | N-[5-(1,2,4-triazole-1-yl)thiazole-2-yl]aryl amide, preparation method, and applications thereof | UNIV HUNAN | 2014-03-26 | — | — | CN | disclosed |
| US-8673948-B2 | Chemical compounds | GlaxoSmithKline, LLC (US) | 2014-03-18 | — | — | US | disclosed |
| CN-102725283-B | Compounds and compositions as protein kinase inhibitors | IRM LLC | 2014-02-26 | — | — | CN | disclosed |
| EP-2043656-B1 | NEW MEDICAL USE OF TRIAZINE DERIVATIVES | UNIV GREENWICH (GB) | 2014-02-12 | — | — | EP | disclosed |
| CN-102596937-B | Compounds and compositions as protein kinase inhibitors | NOVARTIS AG | 2014-02-12 | — | — | CN | disclosed |
| US-20140039194-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2014-02-06 | — | — | US | disclosed |
| US-20140039194-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2014-02-06 | — | — | US | disclosed |
| US-20140039194-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2014-02-06 | — | — | US | disclosed |
| WO-2014022707-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2014-02-06 | — | — | WO | disclosed |
| CN-103524487-A | Sitafloxacin preparation method | NANJING YOKO BIO MEDICAL RES CO LTD | 2014-01-22 | — | — | CN | disclosed |
| EP-2079466-B1 | SUBSTITUTED INDOLE COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2014-01-15 | — | — | EP | disclosed |
| WO-2013177224-A1 | N-SUBSTITUTED BENZAMIDES AND THEIR USE IN THE TREATMENT OF PAIN | GENENTECH, INC. (US) | 2013-11-28 | — | — | WO | disclosed |
| WO-2013129443-A1 | NOVEL PIPERIDINE COMPOUND OR SALT THEREOF | 大鵬薬品工業株式会社 (JP) | 2013-09-06 | — | — | WO | disclosed |
| EP-2017279-B1 | AMINOPYRIMIDINE DERIVATIVES HAVING AURORA-A-SELECTIVE INHIBITORY ACTIVITY | MSD KK (JP) | 2013-09-04 | — | — | EP | disclosed |
| US-8519136-B2 | Aminopyridine derivatives having aurora a selective inhibitory action | MSD K.K. (JP) | 2013-08-27 | — | — | US | disclosed |
| EP-2018364-B1 | THERAPEUTIC FLUOROETHYL UREAS | ALLERGAN INC (US) | 2013-08-21 | — | — | EP | disclosed |
| CN-103209695-A | Azabenzothiazole compounds, compositions and methods of use | HOFFMANN LA ROCHE | 2013-07-17 | — | — | CN | disclosed |
| EP-1813609-B1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING SELECTIVE AURORA-A INHIBITORY EFFECT | MSD KK (JP) | 2013-06-19 | — | — | EP | disclosed |
| CN-103073418-A | Preparation method of 2-fluoro-3-chlorobenzoic acid | NINGBO CHEMGOO PHARMA TECH CO LTD | 2013-05-01 | — | — | CN | disclosed |
| CN-103073418-A | Preparation method of 2-fluoro-3-chlorobenzoic acid | NINGBO CHEMGOO PHARMA TECH CO LTD | 2013-05-01 | — | — | CN | disclosed |
| CN-103073418-A | Preparation method of 2-fluoro-3-chlorobenzoic acid | NINGBO CHEMGOO PHARMA TECH CO LTD | 2013-05-01 | — | — | CN | disclosed |
| EP-1828165-B1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | MSD KK (JP) | 2013-03-20 | — | — | EP | disclosed |
| US-20130005732-A1 | NEW MEDICAL USE OF TRIAZINE DERIVATIVES | UNIVERSITY OF GREENWICH (GB) | 2013-01-03 | — | — | US | disclosed |
| CN-102858754-A | RAF inhibitor compounds and methods of use thereof | ARRAY BIOPHARMA INC | 2013-01-02 | — | — | CN | disclosed |
| EP-2173724-B1 | QUINAZOLINONE COMPOUNDS AND METHODS OF USE THEREOF | ARQULE INC (US) | 2012-12-05 | — | — | EP | disclosed |
| EP-2173724-B1 | QUINAZOLINONE COMPOUNDS AND METHODS OF USE THEREOF | ARQULE INC (US) | 2012-12-05 | — | — | EP | disclosed |
| EP-2197847-B1 | DEUTERATED 4 -OXOQUINOLINE DERIVATIVE FOR THE TREATMENT OF HIV INFECTION | CONCERT PHARMACEUTICALS INC (US) | 2012-11-07 | — | — | EP | disclosed |
| US-8268823-B2 | Medical use of triazine derivatives | UNIVERSITY OF GREENWICH (GB) | 2012-09-18 | — | — | US | disclosed |
| US-8252781-B2 | 1,2-diazetidin-3-one derivatives and drugs containing same | KOWA COMPANY, LTD. (JP) | 2012-08-28 | — | — | US | disclosed |
| US-8232285-B2 | Quinazolinone compounds and methods of use thereof | ARQULE, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232285-B2 | Quinazolinone compounds and methods of use thereof | ARQULE, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232285-B2 | Quinazolinone compounds and methods of use thereof | ARQULE, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-20120071652-A1 | Novel Piperazines, Pharmaceutical Compositions and Methods of Use Thereof | CORNERSTONE THERAPEUTICS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-8101621-B2 | Aminopyridine derivatives having aurora a selective inhibitory action | MSD K.K. (JP) | 2012-01-24 | — | — | US | disclosed |
| US-20110301203-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-12-08 | — | — | US | disclosed |
| WO-2011135481-A1 | USE OF HALOGENATED BENZOIC ACIDS FOR LABELLING INJECTION WATER | TOTAL S.A. (FR) | 2011-11-03 | — | — | WO | disclosed |
| US-20110260051-A1 | METHOD FOR DETECTING TRACER COMPOUNDS FOR HYDROCARBON PRODUCTION | TOTAL S.A. (FR) | 2011-10-27 | — | — | US | disclosed |
| US-20110260051-A1 | METHOD FOR DETECTING TRACER COMPOUNDS FOR HYDROCARBON PRODUCTION | TOTAL S.A. (FR) | 2011-10-27 | — | — | US | disclosed |
| US-20110260051-A1 | METHOD FOR DETECTING TRACER COMPOUNDS FOR HYDROCARBON PRODUCTION | TOTAL S.A. (FR) | 2011-10-27 | — | — | US | disclosed |
| US-8044075-B2 | IL-8 receptor antagonists | GLAXOSMITHKLINE (US) | 2011-10-25 | — | — | US | disclosed |
| EP-2368880-A1 | 6-(Heterocycle-Substituted Benzyl)-4-Oxoquinoline Compound and Use of the Same as HIV Integrase Inhibitor | Japan Tobacco, Inc. (JP) | 2011-09-28 | — | — | EP | disclosed |
| US-8026262-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2011-09-27 | — | — | US | disclosed |
| CN-102186847-A | novel 2-amido thiadiazole derivatives | ALMIRALL SA | 2011-09-14 | — | — | CN | disclosed |
| CN-101506170-B | 6- (heterocycle-substituted benzyl) -4-oxoquinoline compounds and their use as HIV integrase inhibitors | JAPAN TOBACCO INC | 2011-09-14 | — | — | CN | disclosed |
| US-20110217300-A1 | Quinazolinone Compounds and Methods of Use Thereof | ARQULE, INC. (US) | 2011-09-08 | — | — | US | disclosed |
| US-20110217300-A1 | Quinazolinone Compounds and Methods of Use Thereof | ARQULE, INC. (US) | 2011-09-08 | — | — | US | disclosed |
| US-20110217300-A1 | Quinazolinone Compounds and Methods of Use Thereof | ARQULE, INC. (US) | 2011-09-08 | — | — | US | disclosed |
| US-20110200557-A1 | NEW 2-AMIDOTHIADIAZOLE DERIVATIVES | ALMIRALL, S.A. (ES) | 2011-08-18 | — | — | US | disclosed |
| US-7994194-B2 | 4-oxoquinoline derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2011-08-09 | — | — | US | disclosed |
| US-7994194-B2 | 4-oxoquinoline derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2011-08-09 | — | — | US | disclosed |
| EP-2348019-A1 | 1,2-DIAZETIDIN-3-ONE DERIVATIVE AND PHARMACEUTICAL AGENT COMPRISING SAME | Kowa Company, Ltd. (JP) | 2011-07-27 | — | — | EP | disclosed |
| EP-2334670-A1 | NEW 2-AMIDOTHIADIAZOLE DERIVATIVES | Almirall S.A. (ES) | 2011-06-22 | — | — | EP | disclosed |
| US-7943622-B2 | Piperazines, pharmaceutical compositions and methods of use thereof | CORNERSTONE THERAPEUTICS, INC. (US) | 2011-05-17 | — | — | US | disclosed |
| US-7872004-B2 | 6-(heterocyclyl-substituted benzyl)-4-oxoquinoline compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-01-18 | — | — | US | disclosed |
| US-7872004-B2 | 6-(heterocyclyl-substituted benzyl)-4-oxoquinoline compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-01-18 | — | — | US | disclosed |
| US-7872004-B2 | 6-(heterocyclyl-substituted benzyl)-4-oxoquinoline compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-01-18 | — | — | US | disclosed |
| US-20110003833-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-01-06 | — | — | US | disclosed |
| US-20100311749-A1 | 4-BENZOYL-1-SUBSTITUTED-PIPERAZIN-2-ONE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2010-12-09 | — | — | US | disclosed |
| EP-2254888-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | Banyu Pharmaceutical Co., Ltd. (JP) | 2010-12-01 | — | — | EP | disclosed |
| US-20100298387-A1 | IL-8 Receptor Antagonists | SMITHKLINE BEECHAM CORPORATION | 2010-11-25 | — | — | US | disclosed |
| US-7834018-B2 | aurora kinase inhibitors; 2-(thiazol-2-ylamino)pyridine compounds as antitumor agents; 6-((4-(3-chloro-2-fluorobenzoyl)piperazin-1-yl)methyl)-N-thiazol-2-ylpyridin-2-amine for example | BANYU PHARMACEUTICAL CO., LTD (JP) | 2010-11-16 | — | — | US | disclosed |
| CN-101801937-A | Quinazolinone compounds and methods of use thereof | ARQULE INC | 2010-08-11 | — | — | CN | disclosed |
| EP-2212300-A1 | 4-BENZ0YL-1-SUBSTITUTED-PIPERAZIN-2-0NE DERIVATIVES AS P2X7 MODULATORS | Glaxo Group Limited (GB) | 2010-08-04 | — | — | EP | disclosed |
| US-7754886-B2 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES (US) | 2010-07-13 | — | — | US | disclosed |
| US-20100144694-A1 | 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME | KOWA COMPANY, LTD. (JP) | 2010-06-10 | — | — | US | disclosed |
| US-7709507-B2 | Therapeutic fluoroethyl ureas | ALLERGAN, INC. (US) | 2010-05-04 | — | — | US | disclosed |
| WO-2010043377-A1 | NEW 2-AMIDOTHIADIAZOLE DERIVATIVES | ALMIRALL, S.A. (ES) | 2010-04-22 | — | — | WO | disclosed |
| EP-2173724-A2 | QUINAZOLINONE COMPOUNDS AND METHODS OF USE THEREOF | ArQule, Inc. (US) | 2010-04-14 | — | — | EP | disclosed |
| US-20090291954-A1 | Medical Use of Triazine Derivatives | UNIVERSITY OF GREENWICH (GB) | 2009-11-26 | — | — | US | disclosed |
| US-20090264482-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-10-22 | — | — | US | disclosed |
| EP-2099300-A1 | IL-8 RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2009-09-16 | — | — | EP | disclosed |
| WO-2009104802-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-08-27 | — | — | WO | disclosed |
| CN-101506170-A | 6- (heterocycle-substituted benzyl) -4-oxoquinoline compounds and their use as HIV integrase inhibitors | JAPAN TOBACCO INC (JP) | 2009-08-12 | — | — | CN | disclosed |
| US-7572820-B2 | 3-(2-methyl-4-(trifluoromethyl)-5-cyano-indol-1-yl-methyl)-5-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazole or salt thereof; hypogonadism, sarcopenia, osteoporosis, wasting diseases, cancer cachexia, frailty, prostatic hyperplasia, prostate cancer, breast cancer; selective androgen receptor modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-11 | — | — | US | disclosed |
| CN-101497612-A | Novel carbostyrile compound, preparation and use | BEIJING HUAXI UNITED TECHNOLOG (CN) | 2009-08-05 | — | — | CN | disclosed |
| US-20090192174-A1 | Novel Aminopyridine Derivatives Having Aurora a Selective Inhibitory Action | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-07-30 | — | — | US | disclosed |
| EP-2079466-A2 | SUBSTITUTED INDOLE COMPOUNDS | SmithKline Beecham Corporation (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20090149470-A1 | Novel aminopyridine derivatives having aurora a selective inhibitory action | MSD K.K. (JP) | 2009-06-11 | — | — | US | disclosed |
| US-20090143427-A1 | 4-Oxoquinoline derivatives | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2009-06-04 | — | — | US | disclosed |
| US-20090143427-A1 | 4-Oxoquinoline derivatives | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2009-06-04 | — | — | US | disclosed |
| US-20090137585-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090130097-A1 | Quinazolinone Compounds and Methods of Use Thereof | ARQULE, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090130097-A1 | Quinazolinone Compounds and Methods of Use Thereof | ARQULE, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090130097-A1 | Quinazolinone Compounds and Methods of Use Thereof | ARQULE, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| WO-2009053459-A1 | 4-BENZ0YL-1-SUBSTITUTED-PIPERAZIN-2-0NE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2009-04-30 | — | — | WO | disclosed |
| EP-2043656-A2 | NEW MEDICAL USE OF TRIAZINE DERIVATIVES | University of Greenwich (GB) | 2009-04-08 | — | — | EP | disclosed |
| EP-2044038-A2 | NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | Cornerstone Therapeutics Inc. (US) | 2009-04-08 | — | — | EP | disclosed |
| WO-2009035662-A1 | DEUTERATED 4 -OXOQUINOLINE DERIVATIVES FOR THE TREATMENT OF HIV INFECTION | CONCERT PHARMACEUTICALS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| US-7504512-B2 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES (US) | 2009-03-17 | — | — | US | disclosed |
| EP-2033954-A1 | 6-(HETEROCYCLE-SUBSTITUTED BENZYL)-4-OXOQUINOLINE COMPOUND AND USE OF THE SAME AS HIV INTEGRASE INHIBITOR | Japan Tobacco, Inc. (JP) | 2009-03-11 | — | — | EP | disclosed |
| EP-2033954-A1 | 6-(HETEROCYCLE-SUBSTITUTED BENZYL)-4-OXOQUINOLINE COMPOUND AND USE OF THE SAME AS HIV INTEGRASE INHIBITOR | Japan Tobacco, Inc. (JP) | 2009-03-11 | — | — | EP | disclosed |
| US-7491720-B2 | Aminopyridine derivatives having Aurora A selective inhibitory action | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-02-17 | — | — | US | disclosed |
| EP-1542976-B1 | SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | WYETH CORP (US) | 2009-02-04 | — | — | EP | disclosed |
| EP-2018364-A1 | THERAPEUTIC FLUOROETHYL UREAS | Allergan, Inc. (US) | 2009-01-28 | — | — | EP | disclosed |
| EP-2017279-A1 | NOVEL AMINOPYRIDINE DERIVATIVE HAVING AURORA-A-SELECTIVE INHIBITORY ACTIVITY | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-01-21 | — | — | EP | disclosed |
| WO-2009002808-A2 | QUINAZOLINONE COMPOUNDS AND METHODS OF USE THEREOF | ARQULE, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| WO-2009002808-A2 | QUINAZOLINONE COMPOUNDS AND METHODS OF USE THEREOF | ARQULE, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| CN-100415750-C | Fungicides for the control of take-all disease of plants | MONSANTO CO (US) | 2008-09-03 | — | — | CN | disclosed |
| US-20080207618-A1 | 6- (Heterocyclyl-substituted Benzyl) -4-Oxoquinoline Compound and Use Thereof as HIV Integrase Inhibitor | JAPAN TOBACCO INC. (JP) | 2008-08-28 | — | — | US | disclosed |
| US-20080207618-A1 | 6- (Heterocyclyl-substituted Benzyl) -4-Oxoquinoline Compound and Use Thereof as HIV Integrase Inhibitor | JAPAN TOBACCO INC. (JP) | 2008-08-28 | — | — | US | disclosed |
| US-20080207618-A1 | 6- (Heterocyclyl-substituted Benzyl) -4-Oxoquinoline Compound and Use Thereof as HIV Integrase Inhibitor | JAPAN TOBACCO INC. (JP) | 2008-08-28 | — | — | US | disclosed |
| US-20080139631-A1 | 3-(2-methyl-4-(trifluoromethyl)-5-cyano-indol-1-yl-methyl)-5-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazole or salt thereof; hypogonadism, sarcopenia, osteoporosis, wasting diseases, cancer cachexia, frailty, prostatic hyperplasia, prostate cancer, breast cancer; selective androgen receptor modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | US | disclosed |
| WO-2008070707-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008042571-A2 | SUBSTITUTED INDOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-10 | — | — | WO | disclosed |
| US-20080051415-A1 | Novel piperazines, pharmaceutical compositions and methods of use thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH | 2008-02-28 | — | — | US | disclosed |
| US-20080027042-A1 | Novel Aminopyridine Derivatives Having Aurora a Selective Inhibitory Action | OHKUBO MITSURU | 2008-01-31 | — | — | US | disclosed |
| WO-2008007149-A2 | NEW MEDICAL USE OF TRIAZINE DERIVATIVES | UNIVERSITY OF GREENWICH (GB) | 2008-01-17 | — | — | WO | disclosed |
| CN-101103017-A | Novel aminopyridine derivatives having Aurora-A selective inhibitory action | BANYU PHARMA CO LTD (JP) | 2008-01-09 | — | — | CN | disclosed |
| WO-2007146066-A2 | NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | CRITICAL THERAPEUTICS, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007137029-A1 | THERAPEUTIC FLUOROETHYL UREAS | ALLERGAN, INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| US-20070270498-A1 | THERAPEUTIC FLUOROETHYL UREAS | ALLERGAN, INC. | 2007-11-22 | — | — | US | disclosed |
| CN-101054364-A | Substituted 4-(indazol-3-yl)phenols as estrogen receptor (ER) ligands and their use in the treatmentof inflammarory diseases | WYETH CORP (US) | 2007-10-17 | — | — | CN | disclosed |
| US-20070225349-A1 | Substituted 4-(Indazol-3-yl)phenols | WYETH (US) | 2007-09-27 | — | — | US | disclosed |
| EP-1828165-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-09-05 | — | — | EP | disclosed |
| CN-101031541-A | 4-aminomethyl benzamidine derivatives and their use as factor VIIIa inhibitors | HOFFMANN LA ROCHE (CH) | 2007-09-05 | — | — | CN | disclosed |
| EP-1813609-A2 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING SELECTIVE AURORA-A INHIBITORY EFFECT | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-01 | — | — | EP | disclosed |
| US-7241791-B2 | Substituted 4-(indazol-3-yl)phenols | WYETH (US) | 2007-07-10 | — | — | US | disclosed |
| CN-1321984-C | Substituted 4- (indazol-3-yl) phenols as Estrogen Receptor (ER) ligands and their use in the treatment of inflammation | WYETH CORP (US) | 2007-06-20 | — | — | CN | disclosed |
| EP-1791810-A1 | 4-AMINOMETHYL BENZAMIDINE DERIVATIVES AND THEIR USE AS FACTOR VIIA INHIBITORS | F. Hoffmann-Roche AG (CH) | 2007-06-06 | — | — | EP | disclosed |
| US-20060116410-A1 | 4-Aminomethyl benzamidine derivatives | HOFFMANN-LA ROCHE INC. | 2006-06-01 | — | — | US | disclosed |
| US-20060106029-A1 | Novel aminopyridine derivatives having aurora a selective inhibitory action | MSD K.K. (JP) | 2006-05-18 | — | — | US | disclosed |
| CN-1772749-A | Fungicides for the control of take-all disease of plants | MONSANTO CO (US) | 2006-05-17 | — | — | CN | disclosed |
| WO-2006046735-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | WO | disclosed |
| WO-2006027135-A1 | 4-AMINOMETHYL BENZAMIDINE DERIVATIVES AND THEIR USE AS FACTOR VIIIA INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-16 | — | — | WO | disclosed |
| EP-1318978-B1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LAB (US) | 2006-02-08 | — | — | EP | disclosed |
| EP-1369490-B1 | Method of preparing a composition containing hygromycin A and epi-hygromycin | PFIZER PROD INC (US) | 2006-02-08 | — | — | EP | disclosed |
| CN-1239495-C | Bactericide for preventing and treating plant take-all disease | MONSANTO CO (US) | 2006-02-01 | — | — | CN | disclosed |
| CN-1692102-A | Substituted 4- (indazol-3-yl) phenols as Estrogen Receptor (ER) ligands and their use in the treatment of inflammation | WYETH CORP (US) | 2005-11-02 | — | — | CN | disclosed |
| US-20050234090-A1 | Modulators of chemokine receptor activity | PFIZER INC | 2005-10-20 | — | — | US | disclosed |
| EP-1542976-A1 | SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | Wyeth (US) | 2005-06-22 | — | — | EP | disclosed |
| CN-1188419-C | Bactericide for preventing and treating plant take-all disease | MONSANTO CO (US) | 2005-02-09 | — | — | CN | disclosed |
| CN-1188420-C | Fungicides for control of take-all disease of plants | MONSANTO CO (US) | 2005-02-09 | — | — | CN | disclosed |
| US-6821964-B2 | FOR PROPHYLAXIS AND THERAPY OF DISEASES ASSOCIATED WITH MONOCYTE ACCUMULATION, LYMPHOCYTE ACCUMULATION OR LEUCOCYTE ACCUMULATION | PFIZER INC | 2004-11-23 | — | — | US | disclosed |
| US-20040192681-A1 | N-acylsulfonamide apoptosis promoters | ABBVIE INC. | 2004-09-30 | — | — | US | disclosed |
| WO-2004080376-A2 | HYDROXYETHYLAMINE COMPOUNDS HAVING ASP2 INHIBITORY ACTIVITY FOR THE TREATMENT OF ALZHEIMER’S DISEASE | GLAXO GROUP LIMITED (GB) | 2004-09-23 | — | — | WO | disclosed |
| US-20040167127-A1 | Substituted 4-(indazol-3-yl)phenols | WYETH (US) | 2004-08-26 | — | — | US | disclosed |
| WO-2004031159-A1 | SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | WYETH (US) | 2004-04-15 | — | — | WO | disclosed |
| US-6720338-B2 | BCL-X1 INHIBITING COMPOSITIONS AND METHODS OF PROMOTING APOPTOSIS IN A MAMMAL | ABBOTT LABORATORIES | 2004-04-13 | — | — | US | disclosed |
| US-6703387-B2 | STYRYLBENZODIAZEPINES | HOFFMANN-LA ROCHE INC. | 2004-03-09 | — | — | US | disclosed |
| EP-1368354-A1 | MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Pfizer Products Inc. (US) | 2003-12-10 | — | — | EP | disclosed |
| EP-1369490-A1 | Method of preparing a composition containing hygromycin A and epi-hygromycin | Pfizer Products Inc. (US) | 2003-12-10 | — | — | EP | disclosed |
| EP-1075483-B1 | HYGROMYCIN A DERIVATIVES | PFIZER PROD INC (US) | 2003-12-03 | — | — | EP | disclosed |
| EP-1318978-A2 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | Abbott Laboratories (US) | 2003-06-18 | — | — | EP | disclosed |
| EP-1299364-A1 | BENZODIAZEPINES AS INHIBITORS OF HPV E1 HELICASE | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-09 | — | — | EP | disclosed |
| US-6521603-B2 | Amide, thioamide, amidine and thioester derivatives containing a benzene, pyridine, thiophene, furan, pyrrole, pyrazole, thiazole or isothiazole ring | MONSANTO TECHNOLOGY LLC | 2003-02-18 | — | — | US | disclosed |
| US-20030008893-A1 | Modulators of chemokine receptor activity | COLON-CRUZ ROBERTO (US) | 2003-01-09 | — | — | US | disclosed |
| US-20020128262-A1 | Inhibitors of HPV E1 helicase enzyme | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2002-09-12 | — | — | US | disclosed |
| WO-2002070523-A1 | MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | PFIZER PRODUCTS INC. (US) | 2002-09-12 | — | — | WO | disclosed |
| US-20020086887-A1 | N-Acylsulfonamide apoptosis promoters | ABBVIE INC. | 2002-07-04 | — | — | US | disclosed |
| US-6410558-B1 | USING INDOLE OR QUINOLINE COMPOUND | MONSANTO TECHNOLOGY LLC | 2002-06-25 | — | — | US | disclosed |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES | 2002-05-09 | — | — | US | disclosed |
| WO-2002024636-A2 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2002-03-28 | — | — | WO | disclosed |
| WO-2002000632-A1 | BENZODIAZEPINES AS INHIBITORS OF HPV E1 HELICASE | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-03 | — | — | WO | disclosed |
| US-20010046975-A1 | Fungicides for the control of take-all disease of plants | MONSANTO COMPANY | 2001-11-29 | — | — | US | disclosed |
| US-6313100-B1 | ANTIBACTERIAL, ANTIPROTOZOA AGENTS | PFIZER INC | 2001-11-06 | — | — | US | disclosed |
| US-6252078-B1 | Fungicides for the control of take-all disease of plants | MONSANTO COMPANY | 2001-06-26 | — | — | US | disclosed |
| US-6248894-B1 | SUBSTITUTED PYRROLES | MONSANTO COMPANY | 2001-06-19 | — | — | US | disclosed |
| EP-1088481-A2 | Fungicides for the control of take-all disease of plants | MONSANTO COMPANY (US) | 2001-04-04 | — | — | EP | disclosed |
| CN-1063440-C | Process for the desulfurization and the desalting of fossil fuels | RHONE ROULENC AGROCHIMIE CORP (FR) | 2001-03-21 | — | — | CN | disclosed |
| EP-1075483-A2 | HYGROMYCIN A DERIVATIVES | Pfizer Products Inc. (US) | 2001-02-14 | — | — | EP | disclosed |
| US-6166057-A | Fungicides for the control of take-all disease of plants | MONSANTO COMPANY (US) | 2000-12-26 | — | — | US | disclosed |
| US-6133252-A | THIOPHENE AND N-BONDED HETEROCYCLIC COMPOUND CHOSEN FROM THE GROUP CONSISTING OF MORPHOLINE, PIPERAZINE, PIPERIDINE, AND PYRROLIDINE, EACH OPTIONALLY SUBSTITUTED WITH C1-C6 ALKYL GROUPS | MONSANTO COMPANY (US) | 2000-10-17 | — | — | US | disclosed |
| JP-2000247980-A | PRODUCTION OF (-)PYRIDOBENZOXAZINECARBOXYLIC ACID DERIVATIVE | SAMSUNG ELECTRONICS CO LTD | 2000-09-12 | — | — | JP | disclosed |
| US-6028101-A | Fungicides for the control of take-all disease of plants | MONSANTO COMPANY (US) | 2000-02-22 | — | — | US | disclosed |
| US-RE36562-E | CARBOXAMIDE-SUBSTITUTED THIOPHENES | MONSANTO COMPANY (US) | 2000-02-08 | — | — | US | disclosed |
| US-5998466-A | PREPLANTING | MONSANTO COMPANY (US) | 1999-12-07 | — | — | US | disclosed |
| WO-1999057125-A2 | HYGROMYCIN A DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1999-11-11 | — | — | WO | disclosed |
| CN-1225364-A | Fungicides for control of take-all disease of plants | MONSANTO CO (US) | 1999-08-11 | — | — | CN | disclosed |
| CN-1225365-A | Fungicides for control of take-all disease of plants | MONSANTO CO (US) | 1999-08-11 | — | — | CN | disclosed |
| CN-1221745-A | Bactericide for preventing and treating plant take-all disease | MONSANTO CO (US) | 1999-07-07 | — | — | CN | disclosed |
| CN-1221746-A | Bactericide for preventing and treating plant take-all disease | MONSANTO CO (US) | 1999-07-07 | — | — | CN | disclosed |
| US-5849723-A | Fungicides for the control of take-all disease of plants | MONSANTO COMPANY (US) | 1998-12-15 | — | — | US | disclosed |
| US-5834447-A | THIOPHENE DERIVATIVES | MONSANTO COMPANY (US) | 1998-11-10 | — | — | US | disclosed |
| US-5811411-A | Fungicides for the control of take-all disease of plants | MONSANTO COMPANY (US) | 1998-09-22 | — | — | US | disclosed |
| US-5705513-A | HETEROCYCLIC FUNGICIDES WITH PYRIDINE OR FURAN RINGS | MONSANTO COMPANY (US) | 1998-01-06 | — | — | US | disclosed |
| US-5693667-A | Fungicides for the control of take-all disease of plants | MONSANTO COMPANY (US) | 1997-12-02 | — | — | US | disclosed |
| US-5498630-A | SUBSTITUTED BENZOTHIOPHENECARBOXAMIDES | MONSANTO COMPANY (US) | 1996-03-12 | — | — | US | disclosed |
| CN-1085221-A | Bactericide for preventing and treating plant take-all disease | MONSANTO CO (US) | 1994-04-13 | — | — | CN | disclosed |
| CN-1079735-A | Arylpyrazole mycocide | ENERGY BIOSYSTEMS CORP (FR) | 1993-12-22 | — | — | CN | disclosed |
| WO-1993007751-A1 | FUNGICIDES FOR THE CONTROL OF TAKE-ALL DISEASE OF PLANTS | MONSANTO COMPANY (US) | 1993-04-29 | — | — | WO | disclosed |
| EP-0538231-A1 | Fungicides for the control of take-all disease of plants | MONSANTO COMPANY (US) | 1993-04-21 | — | — | EP | disclosed |
| EP-0538231-A1 | Fungicides for the control of take-all disease of plants | MONSANTO COMPANY (US) | 1993-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200054630-A1 | BENZAMIDES-CONTAINING COMPOUNDS AND THEIR USE IN THE TREATMENT OF DEPRESSION | P2RX5, P2RX7, P2RX2 | TSHR 1207/4885ALDH1A1 637/4885NOTUM 2436/4885 |
| US-20020086887-A1 | N-Acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | TSHR 4377/4885ALDH1A1 2651/4885NOTUM 2492/4885 |
| US-11518764-B2 | Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interaction | BCL6, BCL6B, BCL3 | TSHR 3920/4885ALDH1A1 3501/4885NOTUM 3178/4885 |
| US-12275727-B2 | Compound containing structure of a five-membered heteroaromatic ring, pharmaceutical compositions thereof and applications thereof | PARG, CYP3A5, CYP11B1 | TSHR 3826/4885ALDH1A1 749/4885NOTUM 287/4885 |
| US-10092556-B2 | Piperidine compound or salt thereof | TUBB6, KIF5A, TUBB3 | TSHR 904/4885ALDH1A1 3323/4885NOTUM 2914/4885 |
| US-11319299-B2 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | WDR5, WDR82, WDR1 | TSHR 4612/4885ALDH1A1 3236/4885NOTUM 1958/4885 |
| US-20220144829-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA1, ITGAL | TSHR 2320/4885ALDH1A1 1981/4885NOTUM 2452/4885 |
| US-20090264482-A1 | CHEMICAL COMPOUNDS | AR, NR5A1, ESRRA | TSHR 1205/4885ALDH1A1 671/4885NOTUM 293/4885 |
| US-20140039194-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | TYMS, TYMP, POLB | TSHR 4554/4885ALDH1A1 2138/4885NOTUM 2414/4885 |
| US-20220162197-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | EP300, KAT2A, KAT6A | TSHR 3589/4885ALDH1A1 2786/4885NOTUM 2359/4885 |
| US-20230357208-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | EP300, KAT2A, KAT6A | TSHR 3589/4885ALDH1A1 2786/4885NOTUM 2359/4885 |
| US-20070225349-A1 | Substituted 4-(Indazol-3-yl)phenols | INSR, TNNI3, INSRR | TSHR 124/4885ALDH1A1 2279/4885NOTUM 3952/4885 |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | TSHR 4350/4885ALDH1A1 2460/4885NOTUM 2537/4885 |
| US-20040192681-A1 | N-acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | TSHR 4377/4885ALDH1A1 2651/4885NOTUM 2492/4885 |
| US-12264147-B2 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | WDR5, WDR82, WDR1 | TSHR 4612/4885ALDH1A1 3236/4885NOTUM 1958/4885 |
| US-20200331921-A1 | INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | BCL6, BCL6B, BCL3 | TSHR 3819/4885ALDH1A1 3306/4885NOTUM 3463/4885 |
| US-20220411468-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | VIP, ARG1, CX3CR1 | TSHR 267/4885ALDH1A1 4290/4885NOTUM 4562/4885 |
| US-20230131830-A1 | PYRIMIDINE COMPOUNDS AND THEIR PHARMACEUTICAL USES | TYMP, DPYD, TYMS | TSHR 3730/4885ALDH1A1 427/4885NOTUM 1893/4885 |
| US-11072617-B2 | Bicyclic sulfones and sulfoxides and methods of use thereof | RB1, CCNE2, RPS3A | TSHR 2564/4885ALDH1A1 1912/4885NOTUM 4341/4885 |
| US-20180179186-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | CFD, TFPI, CFH | TSHR 2640/4885ALDH1A1 2717/4885NOTUM 3400/4885 |
| US-20090143427-A1 | 4-Oxoquinoline derivatives | CYP3A4, PIK3CA, CYP3A5 | TSHR 4869/4885ALDH1A1 1410/4885NOTUM 2967/4885 |
| US-20190127382-A1 | BICYCLIC SULFONES AND SULFOXIDES AND METHODS OF USE THEREOF | RB1, CCNE2, RPS3A | TSHR 2564/4885ALDH1A1 1912/4885NOTUM 4341/4885 |
| US-11229638-B2 | Therapeutic heterocyclic compounds | SDHA, CYP11B2, ABCB1 | TSHR 2381/4885ALDH1A1 285/4885NOTUM 3000/4885 |
| US-20110217300-A1 | Quinazolinone Compounds and Methods of Use Thereof | NQO2, NQO1, MKI67 | TSHR 4576/4885ALDH1A1 352/4885NOTUM 2910/4885 |
| US-20140107340-A1 | Benzamides | P2RX7, TRPV1, P2RX5 | TSHR 1194/4885ALDH1A1 1424/4885NOTUM 2001/4885 |
| US-20200262818-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | CFD, TFPI, CFH | TSHR 2640/4885ALDH1A1 2717/4885NOTUM 3400/4885 |
| US-20110301203-A1 | CHEMICAL COMPOUNDS | AR, NR5A1, ESRRA | TSHR 1205/4885ALDH1A1 671/4885NOTUM 293/4885 |
| US-10118930-B2 | Piperidinylpyrazolopyrimidinones and their use | HAMP, SERPINC1, PRSS8 | TSHR 3606/4885ALDH1A1 404/4885NOTUM 3074/4885 |
| US-12012466-B2 | Peptide macrocycles against Acinetobacter baumannii | VIP, ARG1, CX3CR1 | TSHR 267/4885ALDH1A1 4290/4885NOTUM 4562/4885 |
| US-20040167127-A1 | Substituted 4-(indazol-3-yl)phenols | INSR, MSR1, TNNI3 | TSHR 256/4885ALDH1A1 1965/4885NOTUM 3969/4885 |
| US-20140343059-A1 | NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | CHRNA7, CHRNA5, CHRNA2 | TSHR 1620/4885ALDH1A1 1032/4885NOTUM 2431/4885 |
| US-20090130097-A1 | Quinazolinone Compounds and Methods of Use Thereof | NQO2, NQO1, MKI67 | TSHR 4576/4885ALDH1A1 352/4885NOTUM 2910/4885 |
| US-20090192174-A1 | Novel Aminopyridine Derivatives Having Aurora a Selective Inhibitory Action | RB1, AURKA, AURKC | TSHR 2388/4885ALDH1A1 1967/4885NOTUM 4701/4885 |
| US-12338241-B2 | Bicyclic sulfones and sulfoxides and methods of use thereof | RB1, CCNE2, RPS3A | TSHR 2564/4885ALDH1A1 1912/4885NOTUM 4341/4885 |
| US-20180369224-A1 | NOVEL PIPERIDINE COMPOUND OR SALT THEREOF | CBR3, PRMT6, PRMT5 | TSHR 310/4885ALDH1A1 2329/4885NOTUM 1461/4885 |
| US-20200109141-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA1, ITGAL | TSHR 2320/4885ALDH1A1 1981/4885NOTUM 2452/4885 |
| US-12338230-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders | CFD, TFPI, CFH | TSHR 2640/4885ALDH1A1 2717/4885NOTUM 3400/4885 |
| US-20120071652-A1 | Novel Piperazines, Pharmaceutical Compositions and Methods of Use Thereof | CHRNA7, CHRNA5, CHRNA2 | TSHR 1620/4885ALDH1A1 1032/4885NOTUM 2431/4885 |
| US-20220289720-A1 | ARYL SULFONAMIDES AS SMALL MOLECULE STAT3 INHIBITORS | STAT3, JAK2, STAT6 | TSHR 1099/4885ALDH1A1 960/4885NOTUM 4699/4885 |
| US-20220315562-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | CFD, TFPI, CFH | TSHR 2640/4885ALDH1A1 2717/4885NOTUM 3400/4885 |
| US-20190192504-A1 | Therapeutic heterocyclic compounds | SDHA, CYP11B2, ABCB1 | TSHR 2381/4885ALDH1A1 285/4885NOTUM 3000/4885 |
| US-10611748-B2 | Xanthone derivatives for the treatment of hepatitis B virus disease | XDH, XPOT, HAVCR2 | TSHR 1684/4885ALDH1A1 1704/4885NOTUM 3837/4885 |
| US-20210053978-A1 | TRICYCLIC INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | BCL6, BCL6B, BCL3 | TSHR 3752/4885ALDH1A1 3794/4885NOTUM 3145/4885 |
| US-11040033-B2 | Therapeutic heterocyclic compounds | SDHA, CYP11B2, ABCB1 | TSHR 2381/4885ALDH1A1 285/4885NOTUM 3000/4885 |
| US-20080027042-A1 | Novel Aminopyridine Derivatives Having Aurora a Selective Inhibitory Action | AURKA, AURKC, AURKB | TSHR 2802/4885ALDH1A1 1644/4885NOTUM 4812/4885 |
| US-20170334917-A1 | PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE | HAMP, SERPINC1, PRSS8 | TSHR 3606/4885ALDH1A1 404/4885NOTUM 3074/4885 |
| US-20010046975-A1 | Fungicides for the control of take-all disease of plants | CNPY3, NAT1, CBR3 | TSHR 391/4885ALDH1A1 3549/4885NOTUM 184/4885 |
| US-11685732-B2 | MYST family histone acetyltransferase inhibitors | EP300, KAT2A, KAT6A | TSHR 3589/4885ALDH1A1 2786/4885NOTUM 2359/4885 |
| US-20100298387-A1 | IL-8 Receptor Antagonists | CXCL8, CCR8, IL1RN | TSHR 772/4885ALDH1A1 2969/4885NOTUM 3612/4885 |
| US-20060106029-A1 | Novel aminopyridine derivatives having aurora a selective inhibitory action | AURKA, AURKC, AURKB | TSHR 2802/4885ALDH1A1 1644/4885NOTUM 4812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.